A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.
about
Daptomycin for the treatment of bacteraemia due to vancomycin-resistant enterococciIdentification of a novel clone, ST736, among Enterococcus faecium clinical isolates and its association with daptomycin nonsusceptibility.Staphylococcus aureus infections: epidemiology, pathophysiology, clinical manifestations, and management.β-Lactams enhance daptomycin activity against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium in in vitro pharmacokinetic/pharmacodynamic models.Daptomycin in the Clinical Setting: 8-Year Experience with Gram-positive Bacterial Infections from the EU-CORE(SM) Registry.Pharmacokinetic and pharmacodynamic considerations of antimicrobial drug therapy in cancer patients with kidney dysfunctionHigh-dose daptomycin therapy for staphylococcal endocarditis and when to apply it.β-Lactam combinations with daptomycin provide synergy against vancomycin-resistant Enterococcus faecalis and Enterococcus faecium.Antimicrobial Stewardship Intervention and Feedback to Infectious Disease Specialists: A Case Study in High-Dose Daptomycin.Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE.Daptomycin for the treatment of major gram-positive infections after cardiac surgery.Fosfomycin Enhances the Activity of Daptomycin against Vancomycin-Resistant Enterococci in an In Vitro Pharmacokinetic-Pharmacodynamic Model.Daptomycin and Its Immunomodulatory Effect: Consequences for Antibiotic Treatment of Methicillin-Resistant Staphylococcus aureus Wound Infections after Heart Surgery.Guidelines for the diagnosis, prevention and management of implantable cardiac electronic device infection. Report of a joint Working Party project on behalf of the British Society for Antimicrobial Chemotherapy (BSAC, host organization), British HeWhen sepsis persists: a review of MRSA bacteraemia salvage therapy.Daptomycin Pharmacokinetics and Pharmacodynamics in Septic and Critically Ill Patients.Clinical experience with the use of daptomycin in a tertiary care teaching hospital in Barcelona, Spain.Should daptomycin-rifampin combinations for MSSA/MRSA isolates be avoided because of antagonism?Incidence, prevalence, and management of MRSA bacteremia across patient populations-a review of recent developments in MRSA management and treatment.False Prolongation of Prothrombin Time in the Presence of a High Blood Concentration of Daptomycin.Differences in Method-Specific Vancomycin MICs and Induced Daptomycin Resistance in an Infective Endocarditis Patient.Study on daptomycin use and implementation of an antimicrobial stewardship program.The Possible Role of Anti-Methicillin-Resistant Staphylococcus Aureus Antimicrobial Agents in Spontaneous Bacterial Peritonitis.2015 ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC). Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the EurWhat's New in the Treatment of Enterococcal Endocarditis?Relationship between consumption of MRSA-active antibiotics and burden of MRSA in acute care hospitals in Catalonia, Spain.Association of Higher Daptomycin Dose (7 mg/kg or Greater) with Improved Survival in Patients with Methicillin-Resistant Staphylococcus aureus Bacteremia.Infective endocarditis.Daptomycin versus teicoplanin for bloodstream infection due to methicillin-resistant Staphylococcus aureus with a high teicoplanin minimal inhibitory concentration ≥1.5 mg/L: a propensity score-based analysis
P2860
Q26851754-B7C1738A-AEAE-4B9F-84C8-83792C8346B1Q34058360-704A4139-B259-406F-BA8D-90B0F1EBE66DQ34478074-A60DF2BE-97AC-45CA-9595-05DA96612DB2Q35385108-2C773B31-0903-4072-B846-24D46387CFA0Q35802607-A410869F-EA51-4216-868C-779710019351Q35819409-0F423A3B-756E-4BEC-A758-A64AA6D6767CQ35848781-F7881133-691C-4AE5-B749-8B6693EBE04FQ35974360-2C3CDD63-39C1-42D3-BD1D-4AA850DFA70FQ36683458-FBDFD30E-AC2A-4724-A92C-D7261CAB4CF1Q36686882-B56C807B-29ED-42B2-9C7A-E8DEF9056B86Q37150644-D9E2303E-DE38-47DE-84AB-ED39ED98EDF8Q37287661-1F622647-F5CB-48C6-B784-22CE452D501BQ38198019-564366F8-1C11-490E-AB9E-C3FA66C6D116Q38263821-AA8FFF44-6337-4B63-9F8D-E7E00B041A9DQ38632488-DC32F15A-1DEF-46F5-9F19-719171F34790Q38895642-E3C960D6-4C9A-4D12-98A3-DBC0A2F32B0CQ38990504-86889136-24FF-49AC-A992-014C9BFF1014Q39488590-D6905BA7-73EA-41E4-B581-602F4BD323F6Q40083539-C9F1AD91-05A8-4C55-9FFD-A6768939829BQ40722135-E76354E5-C8E0-4D87-9684-DB0131D42E0AQ40728255-54844D30-5B19-4F1A-AF2C-056F5ED70863Q40764649-1549B2BE-4DD9-4C45-8BFF-417DCE4247A5Q40837656-CF7531B6-3A26-4C5E-A6AF-8EFBCCF04232Q41026009-25ADCF89-69C4-4A04-A13C-12C06C37B405Q41368979-DCDB6112-D170-43BB-A6B6-653CBEF46C55Q41644243-7D81DA86-90F6-4D6D-B3F0-619E07A8D6AAQ47318913-5CC65646-2AD3-4CB3-B3FF-DCB1ABF109A4Q52943386-577AF154-FDF6-4838-8371-C3EAED5F3E1BQ59135465-C40490BB-0B9F-4F79-ADC4-1C1B8588B4DA
P2860
A multicentre evaluation of the effectiveness and safety of high-dose daptomycin for the treatment of infective endocarditis.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 August 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A multicentre evaluation of th ...... ent of infective endocarditis.
@en
A multicentre evaluation of th ...... ent of infective endocarditis.
@nl
type
label
A multicentre evaluation of th ...... ent of infective endocarditis.
@en
A multicentre evaluation of th ...... ent of infective endocarditis.
@nl
prefLabel
A multicentre evaluation of th ...... ent of infective endocarditis.
@en
A multicentre evaluation of th ...... ent of infective endocarditis.
@nl
P2093
P2860
P356
P1476
A multicentre evaluation of th ...... ent of infective endocarditis.
@en
P2093
Anthony M Casapao
Christopher W Crank
Donald P Levine
George Sakoulas
Jing J Zhao
John Segreti
Michael J Rybak
Ravina Kullar
Sara E Cosgrove
Susan L Davis
P2860
P304
P356
10.1093/JAC/DKT294
P407
P577
2013-08-08T00:00:00Z